Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment [ID6467]

• Awaiting development
• Reference number: GID-TA11585
• Expected publication date: TBC